For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- 7 Drugs Hit 100 Billion Yen Mark in FY2022 Japan Sales, Largest Number in 17 Years
July 24, 2023
- Sosei to Acquire Idorsia’s Japan and Korea Arms for 65 Billion Yen
July 21, 2023
- Lecanemab Shows Large Effect in Low-Tau Population: Clarity AD
July 21, 2023
- ASKA Begins Japan PI/II for Relugolix Combo Drug
July 21, 2023
- Japan Approves Roche’s Mpox Diagnostic
July 20, 2023
- Heavy Demand Triggers Shipment Curb for High-Dose Mounjaro Just 1 Month after Launch
July 20, 2023
- Santen Offloads Entire North American Portfolio to Visiox, Harrow
July 20, 2023
- Kissei Pulls Japan NDA for Spinocerebellar Degeneration Treatment
July 20, 2023
- Remitch OD Tablets Approved in Thailand: Toray/Meiji Pharma
July 20, 2023
- More Crestor Generics Now on Equal Footing with Originator
July 20, 2023
- Anthony Mallet Tapped as Servier Japan Chief
July 19, 2023
- Astellas Becomes 1st Japan Pharma to Sue US Govt over IRA
July 19, 2023
- Roche Group Sues Biogen over Actemra Biosimilar
July 18, 2023
- Meiji’s Stelara Biosimilar Accepted for EU Review
July 18, 2023
- Zolbetuximab Accepted for EMA Review in CLDN18.2 Gastric Cancer: Astellas
July 18, 2023
- Nichi-Iko to Discontinue 258 Products, Largest Number Yet
July 14, 2023
- Gilead Japan Building Sales Force to Prep for Full Oncology Entry: Chief
July 14, 2023
- Enhertu Adds HER2 Low Breast Cancer Nod in China
July 14, 2023
- Daiichi Sankyo Espha Rolls Out Follow-On AG for Maintate
July 13, 2023
- Organon to Succeed Bepricor Distribution from Daiichi Sankyo in Japan
July 13, 2023
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…